Hexaminolevulinate Is Equal to 5-Aminolevulinic Acid Concerning Residual Tumor and Recurrence Rate Following Photodynamic Diagnostic Assisted Transurethral Resection of Bladder Tumors

Urology

Volumn 74, Issue 6, 2009, Pages 1282-1286

  Burger, Maximilian ^a   Stief, Christian G ^b   Zaak, Dirk ^c   Stenzl, Arnulf ^d   Wieland, Wolf F ^a   Jocham, Dieter ^e   Otto, Wolfgang ^a   Denzinger, Stefan ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Clinic Traunstein Trostberg   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TRANSURETHRAL RESECTION;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CARBON RADIOISOTOPES; CYSTECTOMY; CYSTOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PHOTOSENSITIZING AGENTS; RETROSPECTIVE STUDIES; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 70849130933     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.06.088     Document Type: Article

References (29)

1. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 18 3 (2007) 581-592
2. Botteman M.F., Pashos C.L., Redaelli A., et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21 (2003) 1315-1330
3. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 49 (2006) 466-475
4. Kaasinen E. What matters-early start or duration of chemotherapy instillation regimens or patient characteristics?. Eur Urol. 53 5 (2008) 882-885
5. Burger M., van der Aa M.N., van Oers J.M., et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol. 54 4 (2008) 835-844
6. Jakse G., Algaba F., Malmstrom P.U., et al. A second-look TUR in T1 transitional cell carcinoma: why?. Eur Urol. 45 (2004) 539-546
7. Schwaibold H., Sivalingam S., May F., et al. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 97 (2006) 1199-1201
8. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 54 2 (2008) 303-314
9. Sylvester R.J., Oosterlinck W., and Witjes J.A. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 53 4 (2008) 709-719
10. Zaak D., Karl A., Knüchel R., et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int. 96 (2005) 217-222
11. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 178 6 (2007) 2314-2330
12. Marti A., Jichlinski P., Lange N., et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol. 170 2 Pt. 1 (2003) 428-432
13. Jocham D., Stepp H., and Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol. 53 6 (2008) 1138-1148
14. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 174 3 (2005) 862-866 Discussion:866
15. Witjes J.A., Moonen P.M., and van der Heijden A.G. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective phase II study. Eur Urol. 47 3 (2005) 319-322
16. Jichlinski P., Forrer M., Mizeret J., et al. Clinical evaluation of a method for detecting superficial transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following topical application of 5-aminolevulinic acid. Lasers Surg Med. 20 (1997) 402-408
17. Lange N., Jichlinski P., Zellweger M., et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 80 (1999) 185-193
18. Hungerhuber E., Stepp H., Kriegmair M., et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69 2 (2007) 260-264
19. Stenzl A.S., Roessler W., Fradet Y., et al. Hexvix® fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrence: a multicentre, prospective, randomized study. 24th Annual EAU Congress. Eur Urol Suppl. 8 4 (2009) 1010
20. Jichlinski P., Guillou L., Karlsen S.J., et al. Hexylaminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol. 170 1 (2003) 226-229
21. Schmidbauer J., Witjes F., Schmeller N., et al., Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 171 1 (2004) 135-138
22. Grossman H.B., Gomella L., Fradet Y., et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 178 1 (2007) 62-67
23. Fradet Y., Grossman H.B., Gomella L., et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 178 1 (2007) 68-73 discussion:73
24. Filbeck T., Pichlmeier U., Knuechel R., et al. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma?. Urology 60 6 (2002) 1025-1028
25. Babjuk M., Soukup V., Petrík R., et al. 5-Aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 96 6 (2005) 798-802
26. Daniltchenko D.I., Riedl C.R., Sachs M.D., et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol. 174 6 (2005) 2129-2133
27. Denzinger S., Burger M., Walter B., et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69 4 (2007) 675-679
28. Denzinger S., Wieland W.F., Otto W., et al. Does photodynamic transurethral resection of bladder tumor improve the outcome of initial T1 high-grade bladder cancer?. A long-term follow-up of a randomized study. BJU Int. 101 5 (2008) 566-569
29. Burger M., Zaak D., Stief C.G., et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application?. A Germany-based cost analysis. Eur Urol. 52 1 (2007) 142-147